This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Genomic Health Announces Positive Results From Large Study Of Oncotype DX® To Quantify Risk Of Loco-Regional Recurrence In Node-positive Breast Cancer Patients And Acceptance Of Oncotype DX DCIS Validation Study For Publication

REDWOOD CITY, Calif., March 13, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive results of a large study that demonstrates the Oncotype DX® Recurrence Score® result to be a robust predictor of loco-regional recurrence (LRR) in node-positive (N+), estrogen receptor (ER) positive patients treated with adjuvant hormonal therapy and chemotherapy.  This study, titled "Prognostic impact of the 21-gene Recurrence Score (RS) on loco-regional recurrence (LRR) of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28" was recently presented at the 2013 Society of Surgical Oncology Annual Cancer Symposium in National Harbor, Maryland.

"Gaining a better understanding of the patient's individual risk of loco-regional recurrence can assist physicians in determining the most appropriate comprehensive treatment plan," said Terry Mamounas, M.D., Medical Director, Comprehensive Breast  Program, MD Anderson Cancer Center Orlando, and member of the National Surgical Adjuvant Breast and Bowel Project (NSABP) board.  "These new data show that for ER-positive lymph node-positive breast cancer patients, Oncotype DX not only helps identify those who will have excellent outcomes with adjuvant chemo-endocrine therapy, as previously reported, but it can also be useful for radiation treatment decision making."

This study analyzed tumor samples from 1,065 hormone receptor-positive, node-positive breast cancer patients who were treated with hormonal therapy and anthracycline containing chemotherapy as part of the NSABP B-28 trial.  After a median follow-up of 11.2 years, 80 patients had local (68 percent) or regional (32 percent) recurrence. The 10-year cumulative incidence of loco-regional recurrence was 3.3 percent  for patients with a low Recurrence Score result, 7.2 percent for those with an intermediate Recurrence Score result, and 12.3 percent  for those with high Recurrence Score result (p<0.001), demonstrating that the Recurrence Score was significantly associated with the risk of loco-regional recurrence.  These new findings may have clinical implications in node-positive patients treated with adjuvant chemo-endocrine therapy as they consider post-mastectomy chest wall or regional nodal radiotherapy, and post-lumpectomy regional nodal radiotherapy.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs